​

Funding Round

Series E - Vedanta Biosciences

Series E - Vedanta Biosciences

Investment Firm

Overview

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

Announced Date

Apr 25, 2023

Funding Type

Series E

Highlights

Location

United States, North America

Social

Investor Lead

AMR Action Fund

AMR Action Fund

AMR Action Fund is a early_stage_venture and late_stage_venture and post_ipo firm.

AXA Investment Managers

AXA Investment Managers

No designation

Participant Investors

15

Investor Name
Participant InvestorPfizer
Participant InvestorPureTech Health
Participant InvestorBill & Melinda Gates Foundation
Participant InvestorSeventure Partners
Participant InvestorSalica

Round Details and Background

Vedanta Biosciences raised $106500000 on 2023-04-25 in Series E

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

Company Funding History

17

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Apr 25, 2023
Series E - Vedanta Biosciences
18-106.5M
Feb 22, 2024
Venture Round - Vedanta Biosciences
1-undefined
Apr 30, 2024
Grant - Vedanta Biosciences
1-3.9M
Jun 06, 2016
Private Equity Round - Vedanta Biosciences
3-50.0M

Recent Activity

There is no recent news or activity for this profile.